People with blood cancer generally have weakened immune systems, which increases their likelihood of developing severe Covid-19-related illness. Additionally, following Covid-19 immunization, these people acquire little to no antibodies against SARS-CoV-2 due to several cancer treatments. On the other hand, vaccination can trigger T cells, providing the long-lasting immune response.

Experts stated that the study concentrated on patients with B-cell lymphoma and multiple myeloma. It evaluated the amount and quality of antibodies and T cell responses to the spike protein in blood cancer patients and healthy study participants following two and three Covid-19 vaccines.

The findings demonstrated that practically all study participants had a potent T cell response to the Covid-19 immunization. This may have contributed to the mildness and moderate severity of the COVID infections in study individuals who had undergone medication that prevented the development of any particular antibodies following immunization.

The study revealed that people who can generate antibodies tend to do it particularly well. After their second vaccination, they can neutralize and deactivate certain SARS-CoV-2 strains. This ability is noticeably more prominent in this sick cohort than healthy people who have received vaccinations.

Experts also stated that receiving the Covid-19 vaccine might develop very potent neutralizing antibodies in patients with different blood cancer. Hence, patients with multiple myeloma or B-cell lymphoma can receive multiple vaccine doses without interrupting their treatment.

(Source: https://www.tribuneindia.com/news/health/covid-vaccine-protects-patients-with-blood-cancer-study-464086)